ISOBIOTICS Isotopic Labeling of Biotherapeutics
- Coordinator
- Commissariat a L Energie Atomique Et Aux Energies Alternatives, France
- Runs
- 1 February 2023 to 31 January 2027
- Status
- Running
- EU funding
- €2.7m
- Total cost
- —
- Partners
- 18 organisations in 7 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101072780
What the project is doing
In the project's own words, from its summary on CORDIS.
Biological drugs such as peptides, proteins, oligonucleotides and analogs provide the patients with more efficacious and less toxic treatments and have lower attrition rates than chemical drugs since 1 on 9 new biological entities entering clinical trials reaches the market (1 on 16 for chemical drugs). Consequently, 15 on 24 top blockbuster drugs were biotherapeutics in 2020 (world-market share of about 40% of $175 billion of revenue per year).
In order to reduce the immunogenicity of biodrugs, to overcome their fragility and to increase their capacity to reach quickly and massively their target, reduced-size biologics are extensively developed. However, radiolabeling of large molecules by grafting bifunctional chelating agents which do not alter significantly their biological activity is thus no longer possible with smaller biodrugs. It is therefore of paramount importance to devise new radiolabeling approaches carried out on tiny quantities in aqueous media and very soft conditions.
It is also crucial to train a new generation of radiochemists in order to implement these methods and to meet the needs of the European industry. ISOBIOTICS ambitions: 1) to develop new chemically-benign strategies for the last-stage radiolabeling of large peptides, small/medium-size proteins, oligonucleotides and analogs with deuterium, tritium and carbon-14 (preclinical and phase 0 clinical evaluation), and fluorine-18 (phase I-III clinical trials); 2) to educate a new generation of young talented PhD students specialized in the radiolabeling of biologics through a combination of interdisciplinary lab research, transdisciplinary and intersectorial secondments, technical taught courses, scientific lectures and complementary skills workshops; 3) to ensure the appropriate dissemination, exploitation and communication of all ISOBIOTICS outputs in order to maximize the project’s impact and radiance; 4) to secure the students employment and the sustainability of training structures.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Commissariat a L Energie Atomique Et Aux Energies Alternatives | Paris | France | Coordinator |
| Leibniz Institut Fuer Katalyse eV | Rostock | Germany | Associatedpartner |
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Participant |
| Sanofi-Aventis Deutschland GmbH | Frankfurt Am Main | Germany | Participant |
| Aarhus Universitet | Aarhus C | Denmark | Associatedpartner |
| Agencia Estatal Consejo Superior De Investigaciones Cientificas | Madrid | Spain | Associatedpartner |
| Institut Quimic De Sarria | Barcelona | Spain | Associatedpartner |
| Universite Paris-Saclay | Gif-Sur-Yvette | France | Associatedpartner |
| Chemprecise Consultoria Biotecnologia Produtos Farmaceuticos E Imobiliario Lda | Torres Vedras | Portugal | Participant |
| Faculdade De Medicina Da Universidade De Lisboa | Lisboa | Portugal | Associatedpartner |
| Fundacao Gimm - Gulbenkian Institute for Molecular Medicine | Lisboa | Portugal | Participant |
| Faculdade de Farmácia da Universidade de Lisboa | Lisboa | Portugal | Associatedpartner |
| Astrazeneca AB | Sodertaelje | Sweden | Participant |
| Karolinska Institutet | Stockholm | Sweden | Associatedpartner |
| Astrazeneca UK Limited | Cambridge | United Kingdom | Associatedpartner |
| The Chancellor Masters and Scholars of the University of Cambridge | Cambridge | United Kingdom | Associatedpartner |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Associatedpartner |
| The Rosalind Franklin Institute | Didcot | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI